Research on YTS109 Cell in Patients With Recurrent/Refractory Autoimmune Hemolytic Anemia

NCT07453836 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

13

Enrollment

INDUSTRY

Sponsor class

Conditions

Autoimmune Hemolytic Anemia

Interventions

DRUG: YTS109 cell

Sponsor

China Immunotech (Beijing) Biotechnology Co., Ltd.